Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
申请人:Wyeth Holdings Corporation
公开号:US20040127524A1
公开(公告)日:2004-07-01
Hydroxamic acids having the formula
1
are useful in treating disease conditions mediated by TNF-□, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
具有公式1的羟甲酸在治疗由TNF-α介导的疾病情况中具有用处,例如类风湿性关节炎、移植排斥、虚弱、炎症、发热、胰岛素抵抗、脓毒性休克、充血性心力衰竭、中枢神经系统的炎症性疾病、炎症性肠病或HIV感染。